CN115417887A - 一种9-烷基双去氢骆驼蓬碱衍生物及其制备方法和应用 - Google Patents
一种9-烷基双去氢骆驼蓬碱衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115417887A CN115417887A CN202211137128.3A CN202211137128A CN115417887A CN 115417887 A CN115417887 A CN 115417887A CN 202211137128 A CN202211137128 A CN 202211137128A CN 115417887 A CN115417887 A CN 115417887A
- Authority
- CN
- China
- Prior art keywords
- methyl
- carboline
- beta
- ethyl
- harmine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RAYHOJDYVGUYQQ-UHFFFAOYSA-N 7-methoxy-1-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-8-amine;hydrochloride Chemical compound [Cl-].C1CNC(C)C2=C1C1=CC=C(OC)C([NH3+])=C1N2 RAYHOJDYVGUYQQ-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 102000012440 Acetylcholinesterase Human genes 0.000 claims abstract description 13
- 108010022752 Acetylcholinesterase Proteins 0.000 claims abstract description 13
- 229940022698 acetylcholinesterase Drugs 0.000 claims abstract description 13
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 54
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 claims description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 21
- PFFOZZWZWUMENS-UHFFFAOYSA-N chembl1199731 Chemical compound C1=NC(C)=C2N(CC)C3=CC(O)=CC=C3C2=C1 PFFOZZWZWUMENS-UHFFFAOYSA-N 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 16
- COQBVMMHNCHDSD-UHFFFAOYSA-N C1(=CC=C2C(=C1)N(C1=C2C=CN=C1C)C)O Chemical compound C1(=CC=C2C(=C1)N(C1=C2C=CN=C1C)C)O COQBVMMHNCHDSD-UHFFFAOYSA-N 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 15
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 claims description 14
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- LJQLTQRHIJBENP-UHFFFAOYSA-N 7-methoxy-1,9-dimethylpyrido[3,4-b]indole Chemical compound N1=CC=C2C3=CC=C(OC)C=C3N(C)C2=C1C LJQLTQRHIJBENP-UHFFFAOYSA-N 0.000 claims description 12
- IPKUPGYEVPMEEL-UHFFFAOYSA-N N-ethylharmine Chemical compound C1=NC(C)=C2N(CC)C3=CC(OC)=CC=C3C2=C1 IPKUPGYEVPMEEL-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 12
- LVWSZGCVEZRFBT-UHFFFAOYSA-N 1,7-dibromoheptane Chemical compound BrCCCCCCCBr LVWSZGCVEZRFBT-UHFFFAOYSA-N 0.000 claims description 10
- 239000012154 double-distilled water Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 8
- 229960000583 acetic acid Drugs 0.000 claims description 8
- 239000012362 glacial acetic acid Substances 0.000 claims description 8
- 239000005457 ice water Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000012312 sodium hydride Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 5
- 239000000376 reactant Substances 0.000 claims description 5
- 238000005804 alkylation reaction Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000006266 etherification reaction Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000007131 anti Alzheimer effect Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 238000013341 scale-up Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- SZMVXHRECFRCKQ-UHFFFAOYSA-M 2-ethanethioyloxyethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=S)OCC[N+](C)(C)C SZMVXHRECFRCKQ-UHFFFAOYSA-M 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-L 5-[(3-carboxylato-4-nitrophenyl)disulfanyl]-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)[O-])=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C([O-])=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-L 0.000 description 1
- -1 9-ethyldihydroharmine derivative Chemical class 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- FLPIWPOVBBNOCS-UHFFFAOYSA-N [C].[Pr] Chemical compound [C].[Pr] FLPIWPOVBBNOCS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229950008995 aducanumab Drugs 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211137128.3A CN115417887B (zh) | 2022-09-19 | 2022-09-19 | 一种9-烷基双去氢骆驼蓬碱衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211137128.3A CN115417887B (zh) | 2022-09-19 | 2022-09-19 | 一种9-烷基双去氢骆驼蓬碱衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115417887A true CN115417887A (zh) | 2022-12-02 |
CN115417887B CN115417887B (zh) | 2024-02-13 |
Family
ID=84204765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211137128.3A Active CN115417887B (zh) | 2022-09-19 | 2022-09-19 | 一种9-烷基双去氢骆驼蓬碱衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115417887B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116514858A (zh) * | 2023-05-06 | 2023-08-01 | 苏州大学 | 一种去氢骆驼蓬生物碱衍生物、制备方法及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101139347A (zh) * | 2007-10-15 | 2008-03-12 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物类化合物及其应用 |
WO2009047298A2 (en) * | 2007-10-12 | 2009-04-16 | Bioalliance Pharma | Dimers of harmol or of its derivatives and uses thereof |
CN101433565A (zh) * | 2008-11-26 | 2009-05-20 | 上海中医药大学 | 骆驼蓬属种子总生物碱提取物及其有效单体成分和它们的制备与应用 |
CN102636612A (zh) * | 2012-05-14 | 2012-08-15 | 上海中医药大学 | 一种分析骆驼蓬草中有效成分的方法 |
US20130012502A1 (en) * | 2009-12-09 | 2013-01-10 | Hospices Civils De Lyon | Pharmaceutical or Veterinary Antiviral Compositions |
CN104744494A (zh) * | 2013-12-27 | 2015-07-01 | 新疆华世丹药物研究有限责任公司 | 7位双β-咔啉碱类化合物、其制法和其药物组合物与用途 |
-
2022
- 2022-09-19 CN CN202211137128.3A patent/CN115417887B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009047298A2 (en) * | 2007-10-12 | 2009-04-16 | Bioalliance Pharma | Dimers of harmol or of its derivatives and uses thereof |
CN101139347A (zh) * | 2007-10-15 | 2008-03-12 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物类化合物及其应用 |
CN101433565A (zh) * | 2008-11-26 | 2009-05-20 | 上海中医药大学 | 骆驼蓬属种子总生物碱提取物及其有效单体成分和它们的制备与应用 |
US20130012502A1 (en) * | 2009-12-09 | 2013-01-10 | Hospices Civils De Lyon | Pharmaceutical or Veterinary Antiviral Compositions |
CN102636612A (zh) * | 2012-05-14 | 2012-08-15 | 上海中医药大学 | 一种分析骆驼蓬草中有效成分的方法 |
CN104744494A (zh) * | 2013-12-27 | 2015-07-01 | 新疆华世丹药物研究有限责任公司 | 7位双β-咔啉碱类化合物、其制法和其药物组合物与用途 |
Non-Patent Citations (3)
Title |
---|
LIANG GUO ET AL.: "Synthesis and biological evaluation of novel N9-heterobivalent b-carbolines as angiogenesis inhibitors", 《JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY》 * |
YIFAN ZHAO ET AL.: "Design, synthesis and evaluation of novel bivalent β-carboline derivatives as multifunctional agents for the treatment of Alzheimer\'s disease", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
YVONNE ROOK ET AL.: "Bivalent β-Carbolines as Potential Multitarget Anti-Alzheimer Agents", 《J. MED. CHEM.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116514858A (zh) * | 2023-05-06 | 2023-08-01 | 苏州大学 | 一种去氢骆驼蓬生物碱衍生物、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115417887B (zh) | 2024-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102702008B (zh) | 阿戈美拉汀硫酸复合物及其制备方法 | |
CN115417887A (zh) | 一种9-烷基双去氢骆驼蓬碱衍生物及其制备方法和应用 | |
CN105175422B (zh) | 一种磷酸西格列汀晶体及其制备方法和用途 | |
CN103288684B (zh) | 一种具有抗肿瘤活性的联苯脲化合物及其制备方法 | |
Chiacchio et al. | Isoxazolidine analogues of pseudouridine: A new class of modified nucleosides | |
CN102702041A (zh) | 阿戈美拉汀苯磺酸类复合物及其制备方法 | |
CN108017619B (zh) | 一种托匹司他杂质及其制备方法 | |
CN112279883A (zh) | 一种抗肿瘤活性熊果酸衍生物及其制备方法 | |
Denton et al. | Characterization of D-glucaric acid using NMR, X-ray crystal structure, and MM3 molecular modeling analyses | |
CN111433213B (zh) | 作为Akt抑制剂的盐型及其晶型 | |
CN106866625B (zh) | 酮色林的制备方法 | |
Hu et al. | Synthesis of mangiferin derivates and study their potent PTP1B inhibitory activity | |
Reis et al. | Synthesis, spectroscopic characterization and X-ray structure of novel 7-methoxy-4-oxo-N-phenyl-4H-chromene-2-carboxamides | |
CN112608278A (zh) | 一种博舒替尼1,4-哌嗪类二聚体杂质及其制备方法 | |
CN109232576B (zh) | 7-取代脱氧鸭嘴花酮碱及其制备方法和应用 | |
CN117327042B (zh) | 一种规模化制备8,8″-亚甲基-双射干苷元-5′-磺酸钠的方法 | |
CN116496272A (zh) | 7-苄基哌嗪基-9-烯丙基去氢骆驼蓬碱衍生物及其制备方法和应用 | |
RU2248353C2 (ru) | Способ получения морфолиний 3-метил- 1,2,4-триазолил-5-тиоацетата | |
CN111454250B (zh) | 多靶点活性化合物及其用途 | |
CN108640952B (zh) | 一种化合物及其制备方法 | |
CN116036083B (zh) | 吡喃并喹啉酮类化合物在制备治疗宫颈癌药物中的应用 | |
CN110305147B (zh) | 一种苯甲酸衍生物锌配合物及其制备方法和应用 | |
CN112457243B (zh) | 7-溴-5-甲氧基喹啉的合成方法 | |
CN103360457B (zh) | 一种雄甾烷二酮衍生物晶型及其制备方法 | |
CN109400597B (zh) | 一种基于vegfr-2抑制剂abt-869的蛋白降解靶向嵌合体及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Ma Fang Inventor after: Du Hongtao Inventor after: Wang Yanfeng Inventor after: Mao Renjun Inventor after: Bai Zhenqing Inventor after: Yan Yan Inventor before: Du Hongtao Inventor before: Wang Yanfeng Inventor before: Mao Renjun Inventor before: Bai Zhenqing Inventor before: Yan Yan Inventor before: Ma Fang |
|
GR01 | Patent grant | ||
GR01 | Patent grant |